Rapid diagnostic testing of methicillin-resistant Staphylococcus aureus carriage at different anatomical sites: costs and benefits of less extensive screening regimens
| العنوان: | Rapid diagnostic testing of methicillin-resistant Staphylococcus aureus carriage at different anatomical sites: costs and benefits of less extensive screening regimens |
|---|---|
| المؤلفون: | Petra F. G. Wolffs, Marjan W. M. Wassenberg, G.A. de Wit, M.W.H. Wulf, R.W. Bosboom, Marc J. M. Bonten, Annet Troelstra, Steven F. T. Thijsen, Andreas Voss, Willem J. G. Melchers, A.G.M. Buiting, A. A. Van Zwet, Christina M. J. E. Vandenbroucke-Grauls, Jan Kluytmans, Caroline E. Visser, E.P.M. van Elzakker |
| المساهمون: | Medical Microbiology and Infection Prevention, CCA - Immuno-pathogenesis, CCA - Quality of life, Medische Microbiologie, RS: CAPHRI School for Public Health and Primary Care, AII - Amsterdam institute for Infection and Immunity |
| المصدر: | Clinical Microbiology and Infection, 17(11), 1704-1710 Wassenberg, M W M, Kluijtmans, J A J W, Bosboom, R W, Buiting, A G M, van Elzakker, E P M, Melchers, W J G, Thijsen, S F T, Troelstra, A, Vandenbroucke-Grauls, C M J E, Visser, C E, Voss, A, Wolffs, P F G, Wulf, M W H, van Zwet, A A, de Wit, G A & Bonten, M J M 2011, ' Rapid diagnostic testing of methicillin-resistant Staphylococcus aureus carriage at different anatomical sites: costs and benefits of less extensive screening regimens ', Clinical Microbiology and Infection, vol. 17, no. 11, pp. 1704-1710 . https://doi.org/10.1111/j.1469-0691.2011.03502.xTest Clinical Microbiology and Infection, 17(11), 1704-1710. ELSEVIER SCI LTD Clinical microbiology and infection, 17(11), 1704-1710. Elsevier Limited Clinical Microbiology and Infection, 17, 11, pp. 1704-10 Clinical Microbiology and Infection, 17, 1704-10 |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Microbiology (medical), Methicillin-Resistant Staphylococcus aureus, medicine.medical_specialty, food.ingredient, Isolation (health care), Cost effectiveness, Cost-Benefit Analysis, medicine.disease_cause, Microbiology, food, Back-up cultures, stomatognathic system, Predictive Value of Tests, Internal medicine, multiple site screening, medicine, Prevalence, Agar, Humans, Mass Screening, Prospective Studies, cost-effectiveness, MRSA screening, health care economics and organizations, Bacteriological Techniques, GeneXpert MTB/RIF, business.industry, extranasal screening, Pathogenesis and modulation of inflammation Infection and autoimmunity [N4i 1], General Medicine, Staphylococcal Infections, medicine.disease, Methicillin-resistant Staphylococcus aureus, Carriage, Infectious Diseases, rapid diagnostic testing, Staphylococcus aureus, Bacteremia, Carrier State, business |
| الوصف: | Item does not contain fulltext Multiple body site screening and pre-emptive isolation of patients at risk for methicillin-resistant Staphylococcus aureus (MRSA) carriage are considered essential for control of nosocomial spread. The relative importance of extranasal screening when using rapid diagnostic testing (RDT) is unknown. Using data from a multicentre study evaluating BD GeneOhm MRSA PCR (IDI), Xpert MRSA (GeneXpert) and chromogenic agar, added to conventional cultures, we determined cost-effectiveness assuming isolation measures would have been based on RDT results of different hypothetical screening regimes. Costs per isolation day avoided were calculated for regimes with single or less extensive multiple site RDT, regimes without conventional back-up cultures and when PCR would have been performed with pooling of swabs. Among 1764 patients at risk, MRSA prevalence was 3.3% (n = 59). In all scenarios the negative predictive value is above 98.4%. With back-up cultures of all sites as a reference, the costs per isolation day avoided were euro15.19, euro30.83 and euro45.37 with 'nares only' screening using chromogenic agar, IDI and GeneXpert, respectively, as compared with euro19.95, euro95.77 and euro125.43 per isolation day avoided when all body sites had been screened. Without back-up cultures costs per isolation day avoided using chromogenic agar would range from euro9.24 to euro76.18 when costs per false-negative RDT range from euro5000 up to euro50 000; costs for molecular screening methods would be higher in all scenarios evaluated. In conclusion, in a low endemic setting chromogenic agar screening added to multiple site conventional cultures is the most cost-effective MRSA screening strategy. |
| اللغة: | English |
| تدمد: | 1198-743X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dc61ea4c65bc2cfceec7110f10d9b68Test https://doi.org/10.1111/j.1469-0691.2011.03502.xTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3dc61ea4c65bc2cfceec7110f10d9b68 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1198743X |
|---|